Global Bacteremia Market - 2023-2030

Global Bacteremia Market - 2023-2030

Global Bacteremia Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

Bacteremia is the diagnosis used for the presence of bacteria in the blood. Bacteremia can have significant clinical implications and is regarded as a major health problem even though it may not always result in symptoms or serious disease. In order to combat germs that are resistant to antibiotics, new antibiotics and antimicrobial agents have been developed. However, there has not been much of a pipeline for new antibiotics recently.

The focus on antibiotic management programmes aimed at maximising the use of antibiotics and preventing the development of antibiotic resistance has increased as a result of advances in diagnostics, which have led to the development of faster and more accurate methods for identifying the causing bacteria and their antibiotic susceptibility.

Moreover, to improve patient outcomes, early detection of bacteremia and the start of the proper therapy are essential, early detection and intervention are made easier by point-of-care diagnostic tools and increased communication between laboratory and clinical teams are some factors helps boost the bacteremia market size.

Dynamics

The Increasing Number of Product Approvals for the Treatment

Public health issues can arise from bacterial infections, including bacteremia, especially in healthcare facilities where infections can spread rapidly. The regulatory bodies could provide therapies that may reduce the spread of these diseases importance in their approval. The processes of bacterial disease and antibiotic resistance have been clarified due to developments in microbiology, genetics, and molecular biology. Thus the rise of product approvals drives the market growth.

For instance, in May 2023, for the treatment of patients 18 years of age and older who have developed hospital-acquired bacterial pneumonia, bacteremia and ventilator-associated bacterial pneumonia caused on by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex, the Food and Drug Administration (FDA) has approved Xacduro (sulbactam for injection; durlobactam for injection). Sulbactam, a beta-lactam antibiotic and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, are both ingredients in the co-packaged drug Xacduro. Thus, a rise in product approvals contributes in accelerating market expansion.

Rising number of Clinical Trials on Bacteremia

There is an urgent need for novel and more effective treatments due to the rise in antibiotic-resistant bacteria. It can be particularly difficult to treat bacteremia caused on by organisms that are drug-resistant, which is why it is important to develop novel medications.

For instance, in May 2023, the first patient has been dosed in the company's phase 1b/2a clinical trial ('diSArm') of AP-SA02, which is being developed for the treatment of complicated staphylococcus aureus bacteremia. Armata Pharmaceuticals, Inc. is a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

Moreover, in March 2022, as a potential treatment for adult patients with complex urinary tract infections (cUTI), including acute pyelonephritis, Venatorx Pharmaceuticals recently released positive results from its pivotal Phase 3 research testing the investigational novel medication cefepime-taniborbactam. Fourth-generation cephalosporin cefepime is a beta-lactam (BL) antibiotic that is often used. It has been clinically effective against susceptible gram-negative and gram-positive bacteria for more than 20 years. Thus, all of these factors contribute to the market'sgrowth.

Increasing Geriatric Population

Immunosenescence is the term for the immune system's tendency to decline with age. This implies that the body's capacity to detect and combat diseases, including bacterial infections, is reduced. Elderly people might be less able to establish a robust immunological defense against invasive germs. With age, wound healing typically takes longer. The risk of bacteremia is increased by the possibility of open wounds or infections that are harder to treat as a result of this delayed healing.

Thus, the aging population is growing, which also contributes to the market's rapid expansion.For instance, according to Eurostat, the EU population in January 2022, was estimated to be 446.7 million, out of which 21.1% were older individuals aged 65 or over indicating an increase of 0.3 percentage points (pp) to the previous year and an increase of 3.1 pp compared with a decade earlier.

In addition, according to a new report by the United Nations (UN), the number of individuals aged 65 years or above globally is anticipated to increase two folds in the next 30 years. The geriatric population is expected to attain 1.6 billion in 2050, making up over 16% of the world population.

Side Effects Associated with the Treatment

Depending on the specific antibiotic or treatment plan being used, the patient's condition, and other factors, the side effects of treating bacteremia may differ. For instance, antibiotics can cause allergic responses in some people, ranging from minor skin rashes to more serious signs and symptoms like swelling, breathing problems, or anaphylaxis, a severe allergic reaction that can be fatal. Rarely, certain antibiotics might cause side effects that affect the central nervous system, like disorientation, hallucinations, or seizures. Thus, all of these difficulties may hinder market expansion.

Segment Analysis

The global bacteremia market is segmented based on type, infection type, antibiotics, end user and region.

Beta-lactams used to Treat Bacterial Infections

Penicillins and cephalosporins are both examples of beta-lactams that have a rather broad spectrum of activity against a variety of bacteria. They are suitable for actual treatment when the precise bacterium causing the infection has not yet been identified because they are effective against various Gram-positive and Gram-negative bacteria. The bacterial cell wall, which is essential for bacteria to preserve their structural integrity, is the target of beta-lactams.

They prevent the development of the cell wall, which eventually causes the bacteria to be lysed. They are efficient against bacteria that are actively developing due to this method of action. Additionally, the strategies followed by the companies helps to elevate the segment growth. For instance, on November 07, 2022, in order to support enhanced European production capacity for finished dosage form (FDF) penicillins, the most popular class of antibiotics globally, Sandoz announced an additional investment of EUR 50 million.

The latest commitment follows plans to invest more than EUR 100 million in new manufacturing technologies for the production of oral amoxicillin active pharmaceutical ingredient (API) at Kundl, Austria, that were previously announced last year. The manufacturing capacity for FDFs of amoxicillin and other important penicillin products will expand as a result of this investment. Thus above factors helps to srive the segment growth.

Geographical Penetration

Prevalence of the Diseases in the Region

The North American region is anticipated to have significant market expansion, which can mostly be attributed to a developed healthcare system and quicker access to diagnostics, technological developments, awareness of early diagnosis, increased bacteremia prevalence, and the treatment of infectious disorders are anticipated to drive market expansion.

For instance, in the United States alone, according to the CDC, up to 1.7 million people could have bacteremia each year. The most frequent pathogenic agent found inside and outside of hospitals is staphylococcus aureus bacteremia. Staphylococcus aureus bacteremia mortality is higher than that from AIDS, tuberculosis, or viral hepatitis and similar to that from breast or prostate cancer, according to age-adjusted mortality evaluations. Therefore, the prevalence of disease and other factors contribute to the growth of the region.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on healthcare facilities. Infections with respiratory viruses, such as influenza and SARS-CoV-2, put a lot of strain on healthcare systems, leading to an increase in hospitalizations and admissions to hospitals with critical care units.

Blood cultures (BC) are typically taken because these patients may exhibit signs and symptoms of bloodstream infections (BSI). As a result, clinical laboratories process more blood culture vials in the colder months, and automated blood culture equipment may get overloaded. Regarding the COVID-19 pandemic, an increase in blood culture substances during the pandemic's first wave compared to the pre-epidemic period was observed.

By Type
• Transient
• Intermittent

By Infection Type
• Gram-positive Bacterial Infection
• Gram-negative Bacterial Infection

By Antibiotics
• Beta-lactams
• Glycopeptides
• Aminoglycosides
• Fluoroquinolones
• Others

By End User
• Hospitals
• Specialty Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In March 2022, the first Institute for Technological Innovation in Microbiology, BIOASTER, and Pherecydes Pharma, a biotechnology company focusing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced the implementation of a research collaboration to use phages to treat bacteremia (blood infections) caused by the S. aureus, E. Coli, and Pseudomonas aeruginosa bacteria.
• On August 15, 2023, The U.S. Food and Drug Administration (FDA) has approved Venatorx Pharmaceuticals' New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic for the potential treatment of difficult-to-treat drug-resistant gram-negative bacterial infections and viral infections.
• In October 2022, an abstract from the recently completed phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB), has been chosen for a late-breaking oral presentation at IDWeek 2022, according to Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company geared to meeting the needs of patients with severe bacterial and fungal infections.
• On June 08, 2021, Pfizer Inc. announced that the FDA approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for use in adults 18 years of age and older to prevent pneumonia and invasive disease brought on by the 20 pneumococcal serotypes contained in the vaccine.

Competitive Landscape
The major global players in the market include Pfizer, Pherecydes Pharma, Baxter, Novartis AG, Venatorx Pharmaceuticals, HAL, GSK plc, Sandoz, Basilea Pharmaceutica Ltd, Fresenius SE & Co. KGaA and among others.

Why Purchase the Report?
• To visualize the global bacteremia market segmentation based on type, infection type, antibiotics, end user and regions well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of bacteremia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bacteremia market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies